Binds plasma protein, serum protein, or fibrin (e.g., clotting factor, fibrinolytic factor, complement factor, immunoglobulin, apolipoprotein, etc.)

Subclass of:

530 - Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof

530350000 - PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES

530380000 - Blood proteins or globulins, e.g., proteoglycans, platelet factor 4, thyroglobulin, thyroxine, etc.

530386000 - Globulins

530387100 - Immunoglobulin, antibody, or fragment thereof, other than immunoglobulin antibody, or fragment thereof that is conjugated or adsorbed

530389100 - Polyclonal antibody or immunogloblin of identified binding specificity

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application number	Description	Number of patent applications / Date published
530389300	Binds plasma protein, serum protein, or fibrin (e.g., clotting factor, fibrinolytic factor, complement factor, immunoglobulin, apolipoprotein, etc.)	6
20100286375	Carrier molecules - The present invention relates generally to carrier molecules derived from one animal or avian species or strains and which are substantially non-immunogenic when exposed to an immune system from a species or strain of another animal or avian creature. More particularly, the present invention provides deimmunized immunointeractive molecules and even more particular deimmunized antibodies for use in diagnostic and therapeutic applications.	11-11-2010
20110282036	BSA-SPECIFIC ANTIBODIES - The invention relates to antibodies specific to serum albumins. More specifically, the invention relates to camelid single domain antibodies and pentabodies binding to serum albumins of various species with various affinities.	11-17-2011
20120259097	USE OF ANTI-FACTOR XI ANTIBODIES FOR PREVENTION OF THROMBUS FORMATION - The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor XI and that inhibit factor XI activation and/or activity. The factor XI-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor XI activation and/or wherein inhibition of factor XI has a beneficial effect.	10-11-2012
20140194600	USE OF ANTI-FACTOR XI ANTIBODIES FOR PREVENTION OF THROMBUS FORMATION - The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor XI and that inhibit factor XI activation and/or activity. The factor XI-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor XI activation and/or wherein inhibition of factor XI has a beneficial effect.	07-10-2014
20150087813	LIGAND - The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.	03-26-2015
20150307627	SINGLE-DOMAIN ANTIGEN-BINDING PROTEINS THAT BIND MAMMALIAN IGG - The present application relates to antigen-binding proteins that are capable of binding to mammalian IgG. The frame-work regions of the antigen-binding proteins of the application preferably correspond to those of antibodies naturally that are devoid of light chains as may e.g. be found in camelids. The application further relates to nucleic acids that encode such antigen-binding proteins, to immunoadsorbent materials that comprise such proteins, to the uses of such immunoadsorbent materials for the purification of mammalian IgG antibodies and for therapeutic apheresis.	10-29-2015